Cyclacel Pharmaceuticals wants to stop the cycle of disease. The company's main focus is on cancer, but it is also working on treatments for inflammation, type II diabetes, and HIV/AIDS. Its cancer programs, which seek to halt cell cycles related to disease progression, target such ailments as leukemia and non-small cell lung cancer. Cyclacel's R&D operations are supported by commercial products sold through subsidiary ALIGN Pharmaceuticals, including Xclair cream for radiation-induced skin conditions and Numoisyn lozenge and liquid formulas for xerostomia (dry mouth, often related to chemotherapy).